The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
|Slideshows|May 12, 2016
Psychiatry Roundup: April 2016
Author(s)Laurie Martin
When doctor and patient disagree about care at the end of life: one of six issues in the psychiatric news.
Advertisement
Sources:When a Doctor and Patient Disagree About Care at the End of LifeIncrease in Suicide in the United States, 1999â2014Kazakhstan's Mental Health Crisis: 'As Men We Can't Seek Help'Opioid Abuse in Chronic Pain-Misconceptions and Mitigation StrategiesStudy Finds Risks for Teens of Mothers Who Took Certain AntidepressantsOf Blood and TruthMentions are not endorsements.Â
Advertisement
Related to this article
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
5